Management of HIV During Pregnancy

Dolutegravir-containing regimens are preferred, but — for the first time — bictegravir/FTC/TAF is included as an alternative option.

Sponsoring Organization: NIH Office of AIDS Research Advisory Committee, Department of Health and Human Services

Target Audience: Infectious disease specialists, obstetrician-gynecologists.

Background

Previous versions of these guidelines recommended dolutegravir or ritonavir-boosted darunavir plus dual nucleoside reverse transcriptase inhibitors (NRTIs) for HIV treatment during pregnancy. Bictegravir/FTC/TAF, the most commonly used treatment for nonpregnant adults, was not previously recommended because data were insufficient.

Key Recommendations — What's Changed

Preferred initial regimens for pregnant people (and those trying to conceive) who have not previously received antiretroviral drugs are dolutegravir (DTG) plus dual NRTIs; specifically…

Reviewing Author

Rajesh T. Gandhi, MD

Disclosures

Grant/Research SupportNIH

Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)

Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)